Engflag

Menaderm

Quick links to important sections

Menaderm

Menaderm_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Menaderm

What is Menaderm? Defining its Identity and Class

Property Description
Active Ingredients Beclometasone dipropionate, Neomycin sulfate
Form Cream, Ointment, Solution (Topical)
Pharmacological Class Topical Corticosteroid and Aminoglycoside Antibiotic Combination
General Purpose Managing inflammatory skin conditions complicated by bacterial infection
Origin Synthetic

Menaderm is a fixed-dose combination medicine formulated for topical application on the skin, requiring a prescription for use. It is a dual-action agent that combines a potent topical corticosteroid with an aminoglycoside antibiotic, a combination approach utilized in dermatology. The medication is of synthetic origin, specifically designed to leverage two distinct therapeutic actions in a single preparation. The unique feature of the Menaderm formulation is its provision of the potent Beclometasone derivative alongside Neomycin, catering to skin conditions where swift inflammation control and local anti-infective management are simultaneously required.

Active Ingredients: Composition of Beclometasone and Neomycin

The core of Menaderm consists of Beclometasone dipropionate and Neomycin sulfate. Beclometasone is the component primarily responsible for the anti-inflammatory effect and localized relief from itching. Conversely, Neomycin serves as the anti-infective agent against susceptible surface bacteria, functioning to control superficial infections.

The preparation is available as a cream or an ointment, specialized dermatological preparation forms chosen based on the nature of the lesion; the cream is preferred for acute, moist conditions, while the ointment is preferred for chronic, dry conditions.

General Purpose: Dual Action on Skin Conditions

The general purpose of Menaderm is to provide effective, simultaneous relief for mixed etiology skin disorders where inflammation and bacterial presence coexist. This dual-action therapy is typically utilized when inflammatory conditions, such as certain dermatoses, are complicated by a secondary bacterial infection. Combinations of corticosteroids and antibiotics are used to treat inflammatory skin lesions where infection is a factor, offering comprehensive management. This combined approach ensures both the inflammatory response is suppressed and bacterial growth is controlled, optimizing the conditions for skin healing.

Regulatory References

  1. Neomycin Topical (NIH/MedlinePlus)

What side effects are possible with Menaderm?

Possible Side Effects and Safety Information

Menaderm is an anti-inflammatory medicine, typically a topical corticosteroid, and its safety profile is primarily focused on local skin reactions at the application site. Adverse reactions are formally documented and categorized by regulatory authorities in documents like the Summary of Product Characteristics (SmPC).

Adverse Reactions and Safety Scope

Adverse reactions associated with topical corticosteroids and similar anti-inflammatory agents commonly involve the Skin and Subcutaneous Tissue Disorders. These reactions may include local manifestations such as:

  • Irritant or Allergic Contact Dermatitis: Redness, itching, or inflammation where the product is applied, often related to the active ingredient or excipients (e.g., cetyl alcohol, stearic alcohol).
  • Skin Atrophy: Thinning of the skin, a risk often associated with potent corticosteroids and prolonged or extensive use.

More systemic effects, while uncommon with proper topical use, are potential risks, especially with use over large surface areas, for extended durations, or under occlusive dressings. These risks may include adrenal gland alteration in vulnerable populations.

Population-Specific Safety Considerations

Safety precautions are specifically noted for children, where there is a greater risk of systemic absorption of the active substance through the skin. This systemic absorption can lead to adverse effects in other areas of the body, potentially including hormonal alterations or growth retardation. The medicine is often contraindicated or not indicated for use in very young children (e.g., under 1 or 5 years old) without strict medical supervision.

Restrictions and Limitations

Regulatory safety information often specifies situations that require particular caution or restriction:

  • The product should not be used under airtight or waterproof materials (such as certain bandages, dressings, or diapers) as this increases systemic absorption.
  • It should not be used on large areas of skin or for prolonged periods.
  • Contact with the eyes, deep open wounds, or mucous membranes (where absorption is higher) must be strictly avoided.
  • Use in pregnant or breastfeeding women must be weighed carefully by a healthcare professional due to the potential for systemic exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile by detailing the consequences of acute drug toxicity and the required emergency procedures. This content is structured to guide prompt medical action.

Feature Official Regulatory Requirements
Documented Overdose Presentations: Signs, symptoms, and laboratory findings associated with an acute overdosage.
Physiological Systems Affected: Complications that can occur, such as organ toxicity or delayed adverse consequences.
Dose-Related Factors: Where available, information on the single dose amount considered likely to be life-threatening.
Emergency Management: Recommended general treatment procedures and specific measures for supporting vital functions, including any specific, officially recognized antidote.

Required Emergency Actions

If an overdosage is suspected, the regulatory information mandates immediate attention based on the potential for severe or life-threatening outcomes. The official guidance for management includes seeking urgent professional medical assistance. This often involves contacting emergency services or a Poison Control Center immediately.

Connection to the Overdose Profile

The documentation of severe outcomes and toxic effects forms the official basis for determining the urgency of seeking help. The regulatory profile guides healthcare professionals on immediate supportive care and the potential need for specific interventions outlined in the drug's approved prescribing information.

Therapeutic Uses of Menaderm

Quick Facts

  • Primary Use: Management of inflammatory skin conditions.
  • Treats: Acute contact dermatitis, atopic dermatitis, seborrheic eczema, and psoriasis.
  • Action: Helps address redness, itching, and inflammation associated with the skin conditions listed.

Menaderm (containing beclometasone dipropionate) is a prescription topical medication used to assist in the management of specific inflammatory skin conditions in adults and children over five years of age.

The medicine is indicated for the temporary relief of discomfort and visible signs associated with certain skin conditions, primarily by reducing local inflammation and allergic-type reactions in the affected area.

Its therapeutic indications include various forms of dermatitis and eczema, such as acute allergic contact dermatitis, irritative contact dermatitis, atopic dermatitis, neurodermatitis, and seborrheic eczema. Additionally, Menaderm serves as an adjunct in the supportive care of psoriasis. The formulation may be selected based on the skin condition, with creams and emulsions often intended for weeping (exudative) lesions, while the ointment is preferred for dry conditions.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Menaderm, a topical corticosteroid containing beclomethasone dipropionate, is governed by official regulatory documents that strictly define who can and cannot use the medicine. Eligibility is determined primarily by the absence of specific conditions that are formal contraindications.

Populations For Whom Use is Prohibited (Contraindicated)

  • Known Hypersensitivity: The medicine is strictly contraindicated for individuals with a documented allergy (hypersensitivity) to beclomethasone dipropionate, other corticosteroids, or any of the product's inactive ingredients.
  • Untreated Infections: It must not be used on skin lesions caused by active, untreated infections, including those of viral (such as herpes simplex, varicella, vaccinia), bacterial, fungal, or tuberculous origin.
  • Specific Skin Conditions: Use is contraindicated for the treatment of rosacea, acne vulgaris, and perioral dermatitis.

Restricted and Special Consideration Populations

  • Age-Related Eligibility: Use in infants and children is generally restricted or not recommended. Due to a greater risk of systemic absorption and side effects (like HPA axis suppression), long-term or extensive use in pediatric patients is explicitly discouraged by regulatory bodies.
  • Application Site: The product is strictly for topical use on the skin and is not indicated for use in the eyes (ophthalmic use).
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is typically restricted. Official labeling often advises that the medicine should only be used if the potential benefit justifies the potential risk, and extensive or prolonged use should be avoided in pregnant patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Menaderm, as a topical corticosteroid, is generally associated with a low risk of systemic drug-drug interactions due to minimal systemic absorption. However, the potential for interactions exists if significant amounts are absorbed, such as with prolonged use, application over large surface areas, or under occlusive dressings.

Key Documented Interaction Categories

Interacting Product Category Type of Interaction Regulatory Constraint
Strong CYP3A4 Inhibitors (e.g., Ritonavir, Cobicistat) Pharmacokinetic (Increased Exposure) Use with caution; monitor for systemic corticosteroid effects.
Other Corticosteroids (Systemic or Topical) Pharmacodynamic (Additive Effect) Avoid co-administration to mitigate additive risk of HPA axis suppression.
Antidiabetic Agents (e.g., Insulin, Oral Hypoglycemics) Physiological Counter-Effect May reduce the therapeutic efficacy of the antidiabetic agent.

Regulatory information emphasizes that substances which inhibit the CYP3A4 enzyme can significantly increase the systemic concentration of the absorbed corticosteroid. Additionally, combining Menaderm with any other corticosteroid product elevates the cumulative risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression due to additive pharmacodynamic effects. Pediatric patients may be at a higher risk for these systemic effects, necessitating careful consideration of potential interactions.

Mechanism of Action

Menaderm is a synthetic glucocorticoid that operates by passive diffusion across the cell membrane and high-affinity binding to the intracellular glucocorticoid receptors (GRs) present in the cytoplasm of target cells. This binding event initiates a conformational change in the receptor complex. The activated Menaderm-GR complex subsequently translocates into the cell nucleus. Inside the nucleus, the complex functions as a transcription factor, modulating the expression of numerous genes. Its primary mechanistic action involves the transcriptional upregulation of genes encoding anti-inflammatory proteins, such as lipocortin-1 (annexin A1). Concurrently, it directly and indirectly suppresses the transcription of genes responsible for producing pro-inflammatory mediators, including various cytokines (like TNF-alpha and interleukins) and chemokines. This dual modulation leads to the stabilization of cell membranes and a reduction in the release of hydrolytic enzymes from leukocytes. The resulting system-level physiological consequence is a localized decrease in capillary permeability and reduced migration of immune cells to the affected tissue.

Dosage and Administration Information

Administration Scope

Entity Instruction
Route of administration Topical administration to the skin only. The preparation must not be applied to the eyes.
Dosing schedule Apply thinly over the entire affected area and gently rubbed in. Only enough should be applied to cover the entire area.
Timing in relation to meals (if applicable) Not applicable, as the medication is for topical use.
Preparation requirements (if applicable) The choice of dosage form depends on the lesion: Cream is often used for moist or weeping surfaces, and Ointment for dry, scaly lesions.
Age-group administration rules Pediatric Patients: Long-term continuous therapy is avoided, and courses should typically be limited to five days when used in childhood or on the face. The use of a napkin (diaper) on an infant may act as an occlusive dressing, increasing absorption. Older Adults: Suitable for use at the same adult dosage.
Special procedural conditions Beneficial effects may be enhanced by intermittent applications or preliminary use of hot soaks. Avoid prolonged application to the face.

Instruction Classifications

Classification Detail
Administration method type Topical (Dermatological)
Frequency pattern Initially Twice Daily, with intervals extended after improvement to achieve a maintenance dosing every third or fourth day.
Use-context constraints Short-term use only. Treatment should not be continued for more than seven days without re-evaluation. The use of occlusive dressings is avoided due to increased absorption.

Connection to the Overall Use Protocol

Menaderm is administered exclusively via the topical route in a short-term, two-part protocol. The application begins with a twice-daily frequency of a thin layer, which is maintained until improvement is observed. The usage protocol then involves a shift to a lower-frequency maintenance pattern to avoid recurrence. The administration is subject to specific constraints regarding the duration, face application, and the avoidance of occlusive dressings, particularly in children and infants.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Menaderm

Evidence for Use in Corticosteroid-Responsive Skin Conditions

Menaderm was studied for conditions like eczema and psoriasis, which are characterized by fluctuating or episodic manifestations. Research in this area primarily involved short-term controlled trials. These studies examined how symptoms change over defined time intervals, typically lasting a few weeks, which was relevant in trials assessing short-term or episodic symptom patterns.

Researchers monitored several types of outcomes in these trials. These included outcomes related to physical discomfort, such as the severity of itching (pruritus), and outcomes linked to inflammatory or irritative states, such as the redness, scaling, and thickness of the skin. The research describes patterns in measurements observed during the short follow-up periods. Some trials reported measurements related to how symptoms were recorded in the observed populations, comparing those using the active preparation to the inactive vehicle control group.

Overview of Comparative Trial Data

Research was also evaluated in comparative studies where Menaderm was observed in trials alongside an inactive vehicle or sometimes compared to other specific treatments. These studies explored short-term symptom changes and used in research exploring how symptoms change over time. The data show patterns related to how physical signs of the condition were measured in patients receiving the preparation versus those receiving the comparator. The evidence contributes to the broader evidence landscape by summarizing how patient-reported outcomes describing perceived discomfort were recorded across the different treatment groups.

What is Still Uncertain About Menaderm Research

The existing research primarily focuses on acute, short-term treatment. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding the use of the preparation. Data for certain groups remain insufficient, meaning few data are available for groups like younger children, the elderly, or patients with other complex underlying health issues. While the available evidence helps to show what has been observed so far, it provides context but not individual predictions about the full range of outcomes related to its use.

Frequently Asked Questions (FAQ)

Common questions about Menaderm (FAQ)

Q: Why do doctors use Menaderm instead of a different drug for the same problem?

According to official product information, Menaderm is a dual-action medicine. It combines a potent anti-inflammatory agent (Beclometasone) with an antibiotic (Neomycin). This specific combination is described for use in inflammatory skin conditions when they are complicated by a secondary bacterial infection, which requires both actions simultaneously.

Q: Will I experience withdrawal symptoms if I stop using Menaderm?

Official information on the class of medicine (topical corticosteroids) mentions that the original skin condition may worsen or exhibit a rebound effect upon cessation, particularly after prolonged use. Concerns about discontinuing the medicine are typically directed to a healthcare professional.

Q: What happens if Menaderm is used for too long?

Prolonged or extensive use of Menaderm is officially linked to several risks. Locally, this can include skin thinning, known as atrophy. Additionally, it increases the chance of the medicine being systemically absorbed, which may potentially lead to effects on the adrenal glands (HPA axis suppression). The Neomycin component has been associated with risks to the kidneys and hearing when absorbed into the bloodstream.

Q: What is the difference between a cream and an ointment version of Menaderm?

Regulatory documents indicate that the choice of form is based on the condition being treated. The Cream is often cited as being suitable for moist or weeping skin surfaces. Conversely, the Ointment is often noted as being suitable for chronic, dry, scaly lesions, as ointments generally have a more occlusive and greasy base.

Q: Can Menaderm be used with skin moisturizers?

Guidance for this class of medicine suggests a specific approach when using both a medicinal preparation and a moisturizer (emollient). It is suggested that the moisturizer may be applied to the skin first, and a waiting period may be considered before the medicinal cream or ointment is applied.

Q: Can I use Menaderm if I have a fungal or bacterial infection?

The preparation is specified for use in inflammatory skin conditions that are complicated by a secondary bacterial infection, thanks to the antibiotic component. However, the medicine is formally contraindicated, meaning it must not be used, for skin lesions resulting from active, untreated infections of viral, fungal, or tuberculous origin.

Q: Does Menaderm help with itching?

Regulatory documents describe the corticosteroid component of the medicine as providing localized relief from itching (pruritus) associated with the inflammatory skin condition.

Q: Are there food or drink restrictions while using Menaderm?

As the preparation is formulated exclusively for topical use on the skin, regulatory documents indicate that the timing or type of meals is not applicable to the administration of the medicine.

Q: Is it common to feel a stinging sensation when applying Menaderm?

Some reports from authoritative sources indicate that common initial side effects of topical corticosteroids may include a localized stinging or burning sensation when first applied. This sensation is often temporary and can lessen as the skin adjusts to the medicine.

Q: Can Menaderm affect blood sugar levels?

The medicine contains a corticosteroid. While the risk is low with proper topical use, regulatory information includes a warning about the potential for the medicine to reduce the therapeutic efficacy of antidiabetic agents. This suggests that the medicine, if systemically absorbed, could potentially influence blood glucose levels.

Q: Are there any known issues with Menaderm and kidney function?

Regulatory warnings indicate that the class of medicine to which the Neomycin component belongs (aminoglycoside antibiotics) has the potential to be toxic to the kidneys (nephrotoxicity). This potential risk is specifically highlighted when the medicine is used over large areas, for a prolonged duration, or if a person has pre-existing kidney issues.

Q: Does Menaderm cause any changes to skin color or texture?

Adverse reactions associated with topical corticosteroids may include changes to skin texture, most notably skin thinning (atrophy). Less commonly, official sources note that alterations to skin color may occur, which can appear as lighter patches (hypopigmentation) at the application site.

How should Menaderm be stored and disposed of?

The official regulatory documents specify mandatory conditions for the storage and disposal of Menaderm to maintain product quality and ensure environmental safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at a temperature not exceeding 30 °C (for certain forms).
Protection Keep the product out of the sight and reach of children.
Handling Protect from light and heat; Do not freeze (for specific combination products).
Integrity Do not use the medicine after the expiry date shown on the container.

Disposal Instructions

Official disposal protocols require that the unused or expired medicine must not be thrown into household trash or wastewater systems.

To help protect the environment, the product should be returned to a pharmacy’s designated collection point (such as a SIGRE Point) or disposed of according to the local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

flagOman

Equivalent of Menaderm found in:

A-Z Index: